The American Journal of Surgery
Volume 195, Issue 6 , Pages 757-762 , June 2008

Adjuvant gemcitabine plus S-1 chemotherapy after surgical resection for pancreatic adenocarcinoma

Received 8 March 2007 ,Revised 10 April 2007

References 

  1. Jemal A, Siegel R, Ward E, et al. Cancer statistics, 2006. CA Cancer J Clin. 2006;56:106–130
  2. Parkin DM, Bray F, Ferlay J, et al. Global cancer statistics, 2002. CA Cancer J Clin. 2005;55:74–108
  3. Murakami Y, Uemura K, Sasaki T, et al. Long-term survival of pancreatic cancer patient diagnosed by positive telomerase activity of pancreatic juice. Surgery. 2005;138:962–963
  4. Tan HP, Smith J, Garberoglio CA. Pancreatic adenocarcinoma: an update. J Am Coll Surg. 1996;183:164–184
  5. Sener SF, Fremgen A, Menck HR, et al. Pancreatic cancer: a report of treatment and survival trends for 100,313 patients diagnosed from 1985–1995, using the National Cancer Database. J Am Coll Surg. 1999;189:1–7
  6. Winter JM, Cameron JL, Campbell KA, et al. 1423 pancreaticoduodenectomies for pancreatic cancer: A single-institution experience. J Gastrointest Surg. 2006;10:1199–1211
  7. Shimada K, Sakamoto Y, Sano T, et al. Prognostic factors after distal pancreatectomy with extended lymphadenectomy for invasive pancreatic adenocarcinoma of the body and tail. Surgery. 2006;139:288–295
  8. Moon HJ, An JY, Heo JS, et al. Predicting survival after surgical resection for pancreatic ductal adenocarcinoma. Pancreas. 2006;32:37–43
  9. Tani M, Kawai M, Terasawa H, et al. Does postoperative chemotherapy have a survival benefit for patients with pancreatic cancer?. J Surg Oncol. 2006;93:485–490
  10. Brown KM, Domin C, Aranha GV, et al. Increased preoperative platelet count is associated with decreased survival after resection for adenocarcinoma of the pancreas. Am J Surg. 2005;189:278–282
  11. Wagner M, Redaelli C, Lietz M, et al. Curative resection is the single most important factor determining outcome in patients with pancreatic adenocarcinoma. Br J Surg. 2004;91:586–594
  12. Kuhlmann KF, de Castro SM, Wesseling JG, et al. Surgical treatment of pancreatic adenocarcinoma: actual survival and prognostic factors in 343 patients. Eur J Cancer. 2004;40:549–558
  13. Richter A, Niedergethmann M, Sturm JW, et al. Long-term results of partial pancreaticoduodenectomy for ductal adenocarcinoma of the pancreatic head: 25-year experience. World J Surg. 2003;27:324–329
  14. Gebhardt C, Meyer W, Reichel M, et al. Prognostic factors in the operative treatment of ductal pancreatic carcinoma. Langenbecks Arch Surg. 2000;385:14–20
  15. Wenger FA, Peter F, Zieren J, et al. Prognosis factors in carcinoma of the head of the pancreas. Dig Surg. 2000;17:29–35
  16. Sohn TA, Yeo CJ, Cameron JL, et al. Resected adenocarcinoma of the pancreas-616 patients: results, outcomes, and prognostic indicators. J Gastrointest Surg. 2000;4:567–579
  17. Farnell MB, Pearson RK, Sarr MG, et al. Pancreas Cancer Working Group A prospective randomized trial comparing standard pancreatoduodenectomy with pancreatoduodenectomy with extended lymphadenectomy in resectable pancreatic head adenocarcinoma. Surgery. 2005;138:618–630
  18. Yeo CJ, Cameron JL, Sohn TA, et al. Pancreaticoduodenectomy with or without extended retroperitoneal lymphadenectomy for periampullary adenocarcinoma: comparison of morbidity and mortality and short-term outcome. Ann Surg. 1999;229:613–624
  19. Pedrazzoli S, DiCarlo V, Dionigi R, et al. Lymphadenectomy Study Group Standard versus extended lymphadenectomy associated with pancreatoduodenectomy in the surgical treatment of adenocarcinoma of the head of the pancreas: a multicenter, prospective, randomized study. Ann Surg. 1998;228:508–517
  20. Traverso LW. Pancreatic cancer: surgery alone is not sufficient. Surg Endosc. 2006;2(Suppl):S446–S449
  21. Kalser MH, Ellenberg SS. Pancreatic cancer (Adjuvant combined radiation and chemotherapy following curative resection). Arch Surg. 1985;120:899–903
  22. Bakkevold KE, Arnesjo B, Dahl O, et al. Adjuvant combination chemotherapy (AMF) following radical resection of carcinoma of the pancreas and papilla of Vater–results of a controlled, prospective, randomised multicentre study. Eur J Cancer. 1993;29A:698–703
  23. Klinkenbijl JH, Jeekel J, Sahmoud T, et al. Adjuvant radiotherapy and 5-fluorouracil after curative resection of cancer of the pancreas and periampullary region: phase III trial of the EORTC gastrointestinal tract cancer cooperative group. Ann Surg. 1999;230:776–784
  24. Takada T, Amano H, Yasuda H, et al. Study Group of Surgical Adjuvant Therapy for Carcinomas of the Pancreas and Biliary Tract. is postoperative adjuvant chemotherapy useful for gallbladder carcinoma? (A phase III multicenter prospective randomized controlled trial in patients with resected pancreaticobiliary carcinoma). Cancer. 2002;95:1685–1695
  25. Kosuge T, Kiuchi T, Mukai K, et al. Japanese Study Group of Adjuvant Therapy for Pancreatic Cancer (JSAP) A multicenter randomized controlled trial to evaluate the effect of adjuvant cisplatin and 5-fluorouracil therapy after curative resection in cases of pancreatic cancer. Jpn J Clin Oncol. 2006;36:159–165
  26. Neoptolemos JP, Stocken DD, Friess H, et al. European Study Group for Pancreatic Cancer A randomized trial of chemoradiotherapy and chemotherapy after resection of pancreatic cancer. N Engl J Med. 2004;350:1200–1210
  27. Oettle H, Post S, Neuhaus P, et al. Adjuvant chemotherapy with gemcitabine vs observation in patients undergoing curative-intent resection of pancreatic cancer: a randomized controlled trial. JAMA. 2007;297:267–277
  28. Stocken DD, Buchler MW, Dervenis C, et al. Pancreatic Cancer Meta-Analysis Group Meta-analysis of randomised adjuvant therapy trials for pancreatic cancer. Br J Cancer. 2005;92:1372–1381
  29. Shirasaka T, Shimamato Y, Ohshimo H, et al. Development of a novel form of an oral 5-fluorouracil derivative (S-1) directed to the potentiation of the tumor selective cytotoxicity of 5-fluorouracil by two biochemical modulators. Anticancer Drugs. 1996;7:548–557
  30. Tsujie M, Nakamori S, Nakahira S, et al. Schedule-dependent therapeutic effects of gemcitabine combined with Uracil-Tegafur in a human pancreatic cancer xenograft model. Pancreas. 2006;33:142–147
  31. Nakamura K, Yamaguchi T, Ishihara T, et al. Phase II trial of oral S-1 combined with gemcitabine in metastatic pancreatic cancer. Br J Cancer. 2006;94:1575–1579
  32. International Union Against Cancer. TNM Classification of Malignant Tumors. 6th ed.. New York, NY: Wiley-Liss; 2002;
  33. Burris HA, Moore MJ, Andersen J, et al. Improvements in survival and clinical benefit with gemcitabine as first-line therapy for patients with advanced pancreas cancer: a randomized trial. J Clin Oncol. 1997;15:2403–2413
  34. Sakata Y, Ohtsu A, Horikoshi N, et al. Late phase II study of novel oral fluoropyrimidine anticancer drug S-1 (1 M tegafur-0.4 M gimestat-1 M otastat potassium) in advanced gastric cancer patients. Eur J Cancer. 1998;34:1715–1720
  35. Van den Brande J, Schoffski P, Schellens JH, et al. EORTC Early Clinical Studies Group early phase II trial of S-1 in patients with advanced or metastatic colorectal cancer. Br J Cancer. 2003;88:648–653
  36. Ueno H, Okusaka T, Ikeda M, et al. Phase II study of S-1 in patients with advanced biliary tract cancer. Br J Cancer. 2004;91:1769–1774
  37. Ueno H, Okusaka T, Ikeda M, et al. An early phase II study of S-1 in patients with metastatic pancreatic cancer. Oncology. 2005;68:171–178
  38. Picozzi VJ, Kozarek RA, Traverso LW. Interferon-based adjuvant chemoradiation therapy after pancreaticoduodenectomy for pancreatic adenocarcinoma. Am J Surg. 2003;185:476–480
  39. Yeo CJ, Abrams RA, Grochow LB, et al. Pancreaticoduodenectomy for pancreatic adenocarcinoma: postoperative adjuvant chemoradiation improves survival (A prospective, single-institution experience). Ann Surg. 1997;225:621–636
  40. Spitz FR, Abbruzzese JL, Lee JE, et al. Preoperative and postoperative chemoradiation strategies in patients treated with pancreaticoduodenectomy for adenocarcinoma of the pancreas. J Clin Oncol. 1997;15:928–937
  41. Foo ML, Gunderson LL, Nagorney DM, et al. Patterns of failure in grossly resected pancreatic ductal adenocarcinoma treated with adjuvant irradiation +/− 5 fluorouracil. Int J Radiat Oncol Biol Phys. 1993;26:483–489
  42. Whittington R, Bryer MP, Haller DG, et al. Adjuvant therapy of resected adenocarcinoma of the pancreas. Int J Radiat Oncol Biol Phys. 1991;21:1137–1143
  43. Gastrointestinal Tumor Study Group. Further evidence of effective adjuvant combined radiation and chemotherapy following curative resection of pancreatic cancer. Cancer. 1987;59:2006–2010

PII: S0002-9610(08)00070-6

doi: 10.1016/j.amjsurg.2007.04.018

The American Journal of Surgery
Volume 195, Issue 6 , Pages 757-762 , June 2008

Article Tools

* Image Usage & Resolution